Key Highlights

  • Third-quarter 2026 Revenue was $206.7 million, 7.9% below the prior-year $224.5 million and roughly 3% higher sequentially.
  • The company lost $24.4 million, which is $0.84 for each diluted share, against net Earnings of $9.9 million, $0.34 per share, one year prior.
  • Adjusted diluted EPS of $0.14 accompanied adjusted Operating Income of $1.9 million, down from $10.9 million.
  • Management tightened its 2026 revenue forecast to the $850 million to $860 million range.
  • Cash plus investments stood at $453.1 million as of Sep 30, 2026, with no borrowings on the books.

Billing Uncertainty Around Inspire V Drags Revenue Lower

Inspire Medical Systems (NYSE:INSP) closed the period ending Sep 30, 2026, and released its figures on Nov 2, 2026. Sales were $206.7 million, trailing last year's $224.5 million by 7.9% but sitting about 3% above the second quarter. Domestic revenue reached $197.5 million, while international sales declined 8.9% to $9.2 million.

Leadership blamed mainly uncertainty over billing and reimbursement for the newest Inspire V device. By management's count, that hit amounted to about $30 million in the quarter and close to $120 million across 2026. The company sells the Inspire system, a nerve stimulation therapy used where obstructive sleep apnea is moderate or severe.

Year-to-date revenue totaled $611.9 million, a 4.8% reduction, and a Medicare prior-authorization pilot added drag through delayed timing.

Restructuring Costs and a Legal Settlement Push Operating Results Negative

Gross Margin rose from 85.8% to 86.0%, helped by a bigger Inspire V share, which carries a higher margin than the older version, though Volume was lower. Operating expenses climbed by $23.5 million to $206.6 million. Restructuring accounted for $24.1 million of that total, and a legal settlement took another $7.0 million.

The company therefore swung to an operating loss of $28.7 million; a year earlier it had $9.6 million of operating income. Adjusted operating spending came in at $176 million, below $181.8 million, while adjusted operating income closed at $1.9 million, versus $10.9 million a year earlier.

Adjusted EBITDA margin fell by 130 basis points, landing at 18.3%. Taxes came to an effective 2.5% rate, down from 26.7% a year earlier, mostly due to the pre-tax loss and separate tax charges tied to restructuring.

Project Horizon Redirects About $30 Million Annually Into Patient Access

The Aug 3, 2026 initiative, Project Horizon, merges production sites and simplifies the organization. Charges are expected to total approximately $25 million before tax, and $24.1 million has already been booked this quarter. This frees roughly $30 million of annual capacity.

That money goes to field staffing in roughly 40 high-potential markets, direct patient outreach plus stronger prior authorization assistance. The period-end tally showed 306 field clinical representatives and 279 U.S. sales territories.

September 2026 brought approval of a fresh Category I billing code covering single-lead hypoglossal nerve stimulation, which goes live Jan 1, 2028. Inspire V is now the bulk of procedures, Inspire V accounts for most procedures at this point.

Tightened 2026 Ranges Set Up a Fourth-Quarter Sales Bounce and a Modest 2027 Gain

Adjusted EPS is now expected between $1.20 and $1.40, while the diluted result is a loss pegged between $0.10 and $0.36 per share, and the adjusted Operating Margin sits between 4.5% and 5.5%. Full-year revenue is projected at $850 million to $860 million. Management anticipates a material sequential rise in revenue for the fourth quarter, and a low-single-digit increase in revenue during 2027.

Quarterly operating cash generation was $46.4 million, while the year-to-date figure reached $82.5 million. The Balance Sheet remains debt-free, with cash and investments of $453.1 million.